P3.02c-053 Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
نویسندگان
چکیده
منابع مشابه
phase ii study of gemcitabine and cisplatin regimen in advanced non-small cell lung cancer (nsclc).
background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...
متن کاملNivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
PURPOSE Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial. METHODS Fifty-two patients received nivolumab 3 mg/kg intravenously ever...
متن کاملPredictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Background Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However, the association between the clinical parameters and efficacy of nivolumab remains unclear in adva...
متن کاملClinical Biomarkers and Prognosis in Taiwanese Patients with Non-Small Cell Lung Cancer (NSCLC)
Introduction: Lung cancer is the leading cause of cancer death worldwide with poor survival rates. However, the prognostic factors for survival of patients with lung cancer are not well-established. In this study, we examined the impact of routine laboratory biomarkers and traditional factors on survival of patients with non-small cell lung cancer (NSCLC). Method: Secondary data analysis was co...
متن کاملEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J. Vansteenkiste1, D. De Ruysscher2, W. E. E. Eberhardt3, E. Lim4, S. Senan5, E. Felip6 & S. Peters7, on behalf of the ESMO Guidelines Working Group* Respiratory Oncology (Pulmonology), University Hospitals Leuven/KU Leuven, Leuven; Radiation Oncology, University Hospitals Leuven/KU Leuven, Leuven, Belgium; Department of Medical Oncology, West German Cancer Centre, University Hospital, Universi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1848